Navigation Links
VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
Date:2/28/2011

to differ materially from those indicated by such forward-looking statements.  These factors include, but are not limited to, the timing and substance of our response to the FDA's requests from the End of Review meeting, our response to the FDA's complete response letter, or CRL; the feasibility assessment of performing a retrospective observational study of infants born to mothers exposed to 100 mg of topiramate for migraine prophylaxis during pregnancy and the results, if any, from the retrospective observational study, the FDA's interpretation of and agreement with the information VIVUS submitted relating to teratogenicity and cardiovascular safety; the FDA's meeting minutes; the FDA's interpretation of the data from our SEQUEL study, or OB-305; the FDA's requests, if any, to conduct additional clinical trials, provide further analysis of clinical trial data or to conduct retrospective observational studies; substantial competition; the impact on future sales under a limited label and restrictions on distribution; uncertainties of litigation and intellectual property and patent protection; reliance on sole-source suppliers; limited sales and marketing resources and dependence upon third parties; risks related to the development of innovative products; risks related to the failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign  regulations; and our dependence on the performance of our collaborative partners.  As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products.  There are no guarantees that our response to the FDA's CRL or their request stemming from the End of Review meeting will be sufficient to satisfy the FDA's safety concerns, and that the FDA will not require us to conduct any additional clinical or non-clinical observational studies, or that any product will receive regulatory approval for a
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
7. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
8. VIVUS Announces Sale of MUSE Assets to Meda
9. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
10. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
11. VIVUS to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014   Intrexon Corporation (NYSE: ... announced that it has entered into an Exclusive Channel ... of Sanofi (EURONEXT: SAN and NYSE: SNY ... specific family of its marketed Active Pharmaceutical Ingredients (APIs) ... . This collaboration will leverage Intrexon,s proprietary technology ...
(Date:9/2/2014)... Cepheid (NASDAQ: CPHD) announced today the release ... molecular test for rapid, accurate and reliable determination ... RSV infection. The test will be marketed as ... In Vitro Diagnostic Medical Devices, bringing ... Xpert Flu/RSV XC runs on Cepheid,s GeneXpert ® ...
(Date:9/2/2014)... -- Sinovac Biotech Ltd. (NASDAQ: SVA ), a leading ... today announced that the Company,s management will participate in the ... Global Healthcare Conference, to be held at the Grand Hyatt ... Morgan Stanley Asia Pacific Healthcare Day, to be held at ... Aegis Healthcare & Technology Conference, to be held at the ...
Breaking Medicine Technology:Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 2Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 4Sinovac to Participate in Upcoming Investor Conferences 2
... 28, 2011 Burg Simpson Eldredge Hersh & Jardine, P.C., ... delighted to announce that shareholder, Seth. A. Katz, has been ... a member of the Plaintiffs, Steering Committee in the multidistrict litigation ... ASR XL Acetabular Hip System. In August 2010, ...
... 28, 2011 Awarepoint Corporation, a privately held ... with 91 hospital sites contracted consisting of 45,062,013 ... network coverage in U.S. hospitals and 135,265 healthcare ... enterprise-wide U.S. hospital client base for RTLS in ...
Cached Medicine Technology:Burg Simpson Leads National Litigation Against DePuy Orthopaedics, Inc. 2Awarepoint Announces RTLS in Healthcare Leadership with 2010 Results 2Awarepoint Announces RTLS in Healthcare Leadership with 2010 Results 3Awarepoint Announces RTLS in Healthcare Leadership with 2010 Results 4
(Date:9/2/2014)... key to more youthful immune function might already be ... the Journal of Leukocyte Biology ... mice had different responses to Mycobacterium tuberculosis ... reversed by ibuprofen. , "Inflammation in old age can ... Ph.D., a researcher involved in the work from the ...
(Date:9/2/2014)... 02, 2014 According to a ... the leading global authority in medical device market ... is expected to grow to over €2 billion ... increase in the number of procedures for the ... This market includes TURP devices, laser BPH devices, ...
(Date:9/2/2014)... 2014 Nanomedicine is essentially based ... treating and/or prevention of diseases and infections. Nanotechnology-based ... neurological, and oncology diseases. , Nanomedicine is ... various nanoparticles, their medical usages, and their actions ... scope for research in this domain, and scientists ...
(Date:9/2/2014)... September 02, 2014 On Saturday, September 6, ... and fitness fair ¡Vive tu vida! Get Up! Get Moving!®. ... for better health and wellness for people of all ages ... to the public, will be held at Kiest Park Recreation ... to 1:00 pm. , “Since 2007, we have partnered ...
(Date:9/2/2014)... Durable Medical Goods manufacture ThermoTek , announced ... company LeaseQ, Inc. to help customers acquire capital goods ... LeaseQ’s breakthrough finance shopping platform has enabled businesses to ... run their business. , Said LeaseQ Vice President ... sales team to provide customers faster access to capital ...
Breaking Medicine News(10 mins):Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Technology Manufacturer ThermoTek Announces New Partnership with LeaseQ.com to Help More Customers Acquire Equipment Faster and Cheaper 2
... have found out the benefits of oral ZYVOX for ... bacterial infections. They compared data from 80 health care ... of Intravenous Vancomycin. The results show that oral tablets ... of money spent to health clinics compared to vancomycin. ...
... from Children’s Hospital of Boston have reconstructed defective ... researchers used amniotic fluid for growing the sections ... living tissues into lambs, while they were in ... used for altering birth defects. Undifferentiated stem cell ...
... a life of dignity with access to medicines and care ... cancer, say experts on the eve of World Hospice and ... states like Kerala, Maharashtra, Karnataka and Orissa as well as ... administer strong pain killers that make life more bearable., ...
... is calling for concerted action following the recent release ... (WHO). // ,"Preventing Chronic Diseases: A ... global burden of chronic diseases including cardiovascular disease, cancer, ... global action to prevent chronic disease could save the ...
... total abdominal hysterectomy and laparoscopically assisted vaginal hysterectomy ... the advantages of lower morbidity // and faster ... vaginal route, although there is a high feasibility ... gynecologists need to be familiar with surgical techniques. ...
... and obstructive sleep apnea share some common symptoms, due to ... diagnosis. Obstructive sleep apnea (OSA) occurs when the tongue or ... the airway. This can happen more than 50 times an ... last as long as 60 seconds. The problem is twice ...
Cached Medicine News:Health News:Oral use of ZYVOX (Linezolid) is better to Intravenous Vancomycin use for Skin Infections 2Health News:Terminally Ill deserves a better quality of Life 2Health News:Terminally Ill deserves a better quality of Life 3Health News:Reversibility of symptoms of depression using CPAP in patients with obstructive sleep apnea 2
Used for implantation to reinforce soft tissue in the repair of a hernia or body wall defect. Supplied sterile in peel-open packages. Intended for one-time use....
... is a new, portable, light weight, high ... dermatology, cosmetic and plastic surgery, general surgery, ... skin resurfacing, it is the smallest, yet ... the market. It provides an ideal treatment ...
... Surgical Laser System is designed for ... high-power, dual-wavelength system designed for urology, ... surgery, neurosurgery, pulmonary surgery and gastroenterology ... vaporizes and coagulates tissue with minimal ...
... biolitecs sophisticated Ceralas D15/810 diode laser is ... ideal for many soft tissue applications. With ... D15/810 features a flexible fiber optic delivery ... irrigated or dry environments alike.,Compact and portable, ...
Medicine Products: